Progressive myoclonus epilepsy
MONDO:0020074A rare group of disorders characterized by the development of myoclonic and tonic-clonic epileptic seizures associated with progressive degeneration of the nervous system.
Also known as: PME, epilepsy, progressive myoclonic, progressive myoclonic epilepsy, progressive myoclonic epilepsy (disorder) [ambiguous], progressive myoclonus epilepsy, familial progressive myoclonic epilepsy
19 clinical trials for this condition and its sub-types, 5 tagged with Progressive myoclonus epilepsy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Progressive myoclonus epilepsy
-
MERRF syndrome 5 trials
-
Lafora disease 1 trial
2 sub-types
- Myoclonic epilepsy of Lafora 1 0 trials
- Myoclonic epilepsy of Lafora 2 0 trials
-
Unverricht-Lundborg syndrome 1 trial
-
Early-onset Lafora body disease 0 trials
-
Epilepsy, progressive myoclonic, 11 0 trials
-
Epilepsy, progressive myoclonic, 12 0 trials
-
Epilepsy, progressive myoclonic, 1B 0 trials
-
Custom-Made genetic drug targets rare brain disease in first human test
Disease control OngoingThis study tests a personalized medicine called an antisense oligonucleotide, designed specifically for one person with dentatorubral-pallidoluysian atrophy (DRPLA), a rare genetic brain disorder. The treatment aims to reduce seizures and improve quality of life by targeting the …
Phase 1/2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Real-World study tracks Epidyolex's Long-Term impact on seizures
Disease control OngoingThis study follows 158 people in France who are prescribed Epidyolex (a cannabidiol-based medicine) for seizures as part of their normal care. Researchers will track how long people stay on the treatment, side effects, seizure frequency, and changes in daily functioning and quali…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Custom drug targets rare genetic brain disease in First-Ever human test
Disease control OngoingThis study tests a custom-made drug called an antisense oligonucleotide (ASO) designed for one person with dentatorubral-pallidoluysian atrophy (DRPLA), a rare genetic disorder that affects movement and brain function. The drug aims to reduce the harmful effects of the mutated AT…
Phase 1/2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
One-of-a-Kind drug trial targets rare genetic brain disease
Disease control OngoingThis study tests a custom-made genetic medicine (called an antisense oligonucleotide) designed for one person with dentatorubral-pallidoluysian atrophy (DRPLA), a rare inherited brain disorder. The treatment aims to reduce seizures and improve quality of life. Only one participan…
Phase 1/2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New inhaler aims to stop prolonged seizures fast and safely
Symptom relief By invitation onlyThis study tests the long-term safety of an inhaled medication called Staccato alprazolam for people aged 12 and older who have prolonged seizures. About 300 participants will use the inhaler when a seizure starts to see if it stops the seizure quickly and without serious side ef…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC